Lung Injury Following Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1456-1472

  Cooke, Kenneth R ^a   Yanik, Gregory A ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Cellular effectors and development of IPS; Diffuse lung injury significant problem following allogeneic HCT; Evolution of chronic lung injury after HCT; Idiopathic pneumonia syndrome; Lung injury following hematopoietic cell transplantation; Mechanisms of leukocyte recruitment to lung during IPS; Noninfectious, acute lung injury: IPS

Indexed keywords

EID: 84856950241     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch96     Document Type: Chapter

References (151)

1. Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999; 27: 1800-6.
2. Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993; 147(6 Pt 1): 1393-400.
3. Weiner RS, Mortimer MB, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104: 168-75.
4. Quabeck K. The lung as a critical organ in marrow transplantation. Bone Marrow Transplant 1994; 14: S19-28.
5. Crawford S, Longton G, Storb R. Acute graft versus host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1993; 12: 225-31.
6. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997; 63: 1079-86.
7. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-34.
8. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG. Blood 1988; 72: 621-7.
9. Schultz KR, Green GJ, Wensley D et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994; 84: 3212-20.
10. Crawford SW, Pepe M, Lin D, Benedetti F, Deeg HJ. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995; 152: 690-5.
11. Sullivan KM, Mori M, Sanders JE et al. Late complications of allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1992; 10: 127-34.
12. Sanchez J, Torres A, Serrano J et al. Long term follow up of immunosuppressive treatment for obstructive airway disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 403-8.
13. Badier M, Guillot C, Delpierre S, Vanuxem P, Blaise D, Maraninchi D. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12: 457-61.
14. Quigley PM, Yeager AM, Loughlin GM. The effects of bone marrow transplantation on pulmonary function in children. Pediatric Pulmonology 1994; 18: 361-7.
15. Boeckh M, Ljungman P. Cytomegalovirus infection after hematopoietic stem cell transplantation. In: Bowden RA, Ljungman P, Paya VP, editors. Transplant Infections. Philadelphia: Lippincott- Williams & Wilkins; 2002. pp. 277-97.
16. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 2000; 6: 280-8.
17. Reusser P. Cytomegalovirus infection and disease after bone marrow transplantation: epidemiology, prevention, and treatment. Bone Marrow Transplant 1991; 7(Suppl 3): 52-6.
18. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-60.
19. Shimada A, Koga T, Shimada M et al. Cytomegalovirus pneumonitis presenting small nodular opacities. Intern Med 2004; 43: 1198-200.
20. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 2005; 72: 263-9.
21. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH Jr. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109: 203-8.
22. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987-93.
23. Boeckh M, Englund J, Li Y et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245-9.
24. van den Hoogen BG, Herfst S, Sprong L et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004; 10: 658-66.
25. Englund JA, Boeckh M, Kuypers J et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144: 344-9.
26. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529-33.
27. Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147(6 Pt 1): 1601-6.
28. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-75.
29. Yanik G, Hellerstedt B, Custer J et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 395-400.
30. Robbins RA, Linder J, Stahl MG et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989; 87: 511-18.
31. Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000; 26: 539-43.
32. Metcalf JP, Rennard SI, Reed EC et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 1994; 96: 327-34.
33. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infectionassociated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006; 12: 1038-46.
34. Capizzi SA, Kumar S, Huneke NE et al. Periengraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 1299-303.
35. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157: 565-73.
36. Bhalla KS, Wilczynski SW, Abushamaa AM et al. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000; 161: 17-25.
37. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clincial manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-84.
38. Aronin PA, Mahaley MS Jr., Rudnick SA et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 1980; 303: 183-8.
39. Alessandrino EP, Bernasconi P, Colombo A et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309-13.
40. Shen YC, Chiu CF, Chow KC, Chen CL, Liaw YC, Yeh SP. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant 2004; 34: 609-14.
41. Silliman CC, Boshkov LK, Mehdizadehkashi Z et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101: 454-62.
42. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287: 1968-71.
43. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003; 43: 177-84.
44. Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti- HLA class II antibodies in TRALI. Transfusion 2003; 43: 185-91.
45. Weiner RS, Horowitz MM, Gale RP et al. Risk factors for interstitial pneumonitis following bone marrow transplantation for severe aplastic anemia. Br J Haematol 1989; 71: 535-43.
46. Atkinson K, Turner J, Biggs JC, Dodds A, Concannon A. An acute pulmonary syndrome possibly representing acute graft-versus-host disease involving the lung interstitium. Bone Marrow Transplant 1991; 8: 231-4.
47. Della Volpe A, Ferreri AJ, Annaloro C et al. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys 2002; 52: 483-8.
48. Fukuda T, Hackman RC, Guthrie KA et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777-85.
49. Down JD, Mauch P, Warhol M, Neben S, Ferrara JLM. The effect of donor T lymphocytes and total-body irradiation on hemopoietic engraftment and pulmonary toxicity following experimental allogeneic bone marrow transplantation. Transplantation 1992; 54: 802-8.
50. Shankar G, Cohen DA. Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Int J Exp Pathol 2001; 82: 101-13.
51. Bortin M, Ringden O, Horowitz M, Rozman C, Weiner R, Rimm A. Temporal relationships between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplant 1989; 4: 339-44.
52. Beschorner W, Saral R, Hutchins G, Tutschka P, Santos G. Lymphocytic bronchitis associated with graft versus host disease in recipients of bone marrow transplants. N Engl J Med 1978; 299: 1030-6.
53. Piguet PF, Grau GE, Collart MA, Vassalli P, Kapanci Y. Pneumopathies of the graft-versushost reaction. Alveolitis associated with an increased level of tumor necrosis factor MRNA and chronic interstitial pneumonitis. Lab Invest 1989; 61: 37-45.
54. Clark JG, Madtes DK, Hackman RC, Chen W, Cheever MA, Martin PJ. Lung injury induced by alloreactive Th1 cells is characterized by hostderived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol 1998; 161: 1913-20.
55. Cooke KR, Kobzik L, Martin TR et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-9.
56. Cooke KR, Krenger W, Hill G et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 1998; 92: 2571-80.
57. Panoskaltsis-Mortari A, Taylor PA, Yaegar TM et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogenic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 1997; 100: 1015-27.
58. Cooke KR, Kobzik L, Teshima T, Lowler K, Clouthier S, Ferrara JLM. A role for Fas-Fas ligand but not perforin mediated cytolysis in the development of experimental idiopathic pneumonia syndrome. Blood 2000; 96(Suppl 1): 768a.
59. Gerbitz A, Ewing P, Olkiewicz K et al. A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome. Transplantation 2005; 79: 536-42.
60. Sloane J, Depledge M, Powles R, Morgenstern G, Trickey B, Dady P. Histopathology of the lung after bone marrow transplantation. J Clin Pathol 1983; 36: 546-54.
61. Curtis DJ, Smale A, Thien F, Schwarer AP, Szer J. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 169-73.
62. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for air-flow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-56.
63. Schwarer AP, Hughes JMB, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplant 1992; 54: 1002-8.
64. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170: 655-63.
65. Cooke KR, Hill GR, Gerbitz A et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272-9.
66. Cooke KR, Gerbitz A, Crawford JM et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-9.
67. Piguet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280-9.
68. Cooke KR, Hill GR, Gerbitz A et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol 2000; 165: 6612-19.
69. Hildebrandt GC, Olkiewicz KM, Corrion LA et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 104: 586-93.
70. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990; 87: 3127-31.
71. Shukla M, Yang S, Milla C, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Absence of host tumor necrosis factor receptor 1 attenuates manifestations of idiopathic pneumonia syndrome. Am J Physiol Lung Cell Mol Physiol 2005; 288: L942-9.
72. Hildebrandt GC, Olkiewicz KM, Corrion LA et al. A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome. Biol Blood Marrow Transplant 2008; 14: 385-96.
73. Clark JG, Mandac JB, Dixon AE, Martin PJ, Hackman RC, Madtes DK. Neutralization of tumor necrosis factor-alpha action delays but does not prevent lung injury induced by alloreactive T helper 1 cells. Transplantation 2000; 70: 39-43.
74. Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Yang S, Milla CE, Blazar BR. High levels of peroxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation. Am J Respir Cell Mol Biol 1999; 20: 1125-35.
75. Qureshi MA, Girgis RE, Dandapantula HK, Abrams J, Soubani AO. Increased exhaled nitric oxide following autologous peripheral hematopoietic stem-cell transplantation: a potential marker of idiopathic pneumonia syndrome. Chest 2004; 125: 281-7.
76. Yanik G, Ho VT, Levine JE et al. The impact of soluble tumor necrosis factor receptor:etanercept on the treatment of idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Blood. Epub 2008 July 29.
77. Blackwell TS, Christman JW, Hagan T et al. Oxidative stress and NF-kappaB activation: correlation in patients following allogeneic bone marrow transplantation. Antioxid Redox Signal 2000; 2: 93-102.
78. Cetin T, Arpaci F, Yilmaz MI et al. Oxidative stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell transplantation. Biol Trace Elem Res 2004; 97: 237-47.
79. Bhalla KS, Folz RJ. Idiopathic pneumonia syndrome after syngeneic bone marrow transplant in mice. Am J Respir Crit Care Med 2002; 166(12 Pt 1): 1579-89.
80. Ziegler TR, Panoskaltsus-Mortari A, Gu LH et al. Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation. Transplantation 2001; 72: 1354-62.
81. Hiroyasu S, Shiraishi M, Koji T et al. Analysis of Fas system in pulmonary injury of graftversus- host disease after rat intestinal transplantation. Transplantation 1999; 68: 933-8.
82. Hashimoto S, Kobayashi A, Kooguchi K, Kitamura Y, Onodera H, Nakajima H. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 237-43.
83. Dupuis M, McDonald DM. Dendritic-cell regulation of lung immunity. Am J Respir Cell Mol Biol 1997; 17: 284-6.
84. Holt PG, Haining S, Nelson DJ, Sedgwick JD. Origin and steady-state turnover of class II MHCbearing dendritic cells in the epithelium of the conducting airways. J Immunol 1994; 153: 256-61.
85. Hildebrandt GC, Olkiewicz KM, Choi S et al. Donor T-cell production of RANTES signifi- cantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood 2005; 105: 2249-57.
86. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002; 8: 441-8.
87. Maus U, Herold S, Muth H et al. Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol 2001; 280: L58-68.
88. Elssner A, Vogelmeier C. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. Transpl Infect Dis 2001; 3: 168-76.
89. Martin TR, Goodman RB. The role of chemokines in the pathophysiology of the acute respiratory distress syndrome (ARDS). In: Hebert CA, editor. Chemokines in Disease. Totowa: Humana Press; 1999. pp. 81-110.
90. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
91. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7: 803-15.
92. Gerbitz A, Nickoloff BJ, Olkiewicz K et al. A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation 2004; 78: 494-502.
93. Panoskaltsis-Mortari A, Hermanson JR, Haddad IY, Wangensteen OD, Blazar BR. Intercellular adhesion molecule-I (ICAM-I, CD54) deficiency segregates the unique pathophysiological requirements for generating idiopathic pneumonia syndrome (IPS) versus graft-versus-host disease following allogeneic murine bone marrow transplantation. Biol Blood Marrow Transplant 2001; 7: 368-77.
94. Blazar BR, Taylor PA, Panoskaltis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1: ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graftversus- host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995; 85: 2607-18.
95. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
96. Hildebrandt GC, Duffner UA, Olkiewicz KM et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 103: 2417-26.
97. Panoskaltsis-Mortari A, Strieter RM, Hermanson JR et al. Induction of monocyte- and T-cellattracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation. Blood 2000; 96: 834-9.
98. Dixon AE, Mandac JB, Madtes DK, Martin PJ, Clark JG. Chemokine expression in Th1 cellinduced lung injury: prominence of IFN-gammainducible chemokines. Am J Physiol Lung Cell Mol Physiol 2000; 279: L592-9.
99. Hildebrandt GC, Corrion LA, Olkiewicz KM et al. Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 2004; 173: 2050-9.
100. Serody JS, Burkett SE, Panoskaltsis-Mortari A et al. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-80.
101. Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 2003; 101: 3714-21.
102. Choi SW, Hildebrandt GC, Olkiewicz KM et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 2007; 110: 3447-55.
103. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 23-32.
104. Panoskaltsis-Mortari A, Ingbar DH, Jung P et al. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol 2000; 278: L988-99.
105. Yanik G et al. Impact of broncho-alveolar lavage on the diagnosis and management of pulmonary complications post transplant. Biol Blood Marrow Transplant 2008; 14: 89.
106. Yanik GA, Levine JE, Ferrara JLM et al. Survival following etanercept therapy for the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Blood 2004; 104: 104a.
107. Cerveri I, Zoia MC, Fulgoni P et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54: 131-5.
108. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749-59.
109. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003; 102: 3822-8.
110. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-76.
111. Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis 1984; 129: 641-4.
112. Chien JW, Martin PJ, Gooley TA et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-14.
113. Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 759-64.
114. Wyatt SE, Nunn P, Hows JM et al. Airways obstruction associated with graft-versus-host disease after bone marrow transplantation. Thorax 1984; 39: 887-94.
115. Crawford SW, Clark JG. Bronchiolitis associated with bone marrow transplantation. Clin Chest Med 1993; 14: 741-9.
116. Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-16.
117. Ooi GC, Peh WC, Ip M. High-resolution computed tomography of bronchiolitis obliterans syndrome after bone marrow transplantation. Respiration 1998; 65: 187-91.
118. Parimon T, Madtes DK, Au DH, Clark JG, Chien JW. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med 2005; 172: 384-90.
119. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-14.
120. Chien JW, Maris MB, Sandmaier BM, Maloney DG, Storb RF, Clark JG. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 288-96.
121. Watkins TR, Chien JW, Crawford SW. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Semin Respir Crit Care Med 2005; 26: 482-9.
122. Boehler A, Bai XH, Liu M et al. Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med 1999; 159: 1910-17.
123. Belperio JA, DiGiovine B, Keane MP et al. Interleukin- 1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002; 73: 591-9.
124. Elssner A, Jaumann F, Dobmann S et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation 2000; 70: 362-7.
125. Fattal-German M, Le Roy Ladurie F, Cerrina J, Lecerf F, Berrih-Aknin S. Expression and modulation of ICAM-1, TNF-alpha and RANTES in human alveolar macrophages from lungtransplant recipients in vitro. Transpl Immunol 1998; 6: 183-92.
126. El-Gamel A, Sim E, Hasleton P et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828-37.
127. Belperio JA, Keane MP, Burdick MD et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001; 108: 547-56.
128. Belperio JA, Burdick MD, Keane MP et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 2000; 165: 461-72.
129. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998; 11: 1218-21.
130. Hogaboam CM, Smith RE, Kunkel SL. Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Proc Assoc Am Physicians 1998; 110: 313-20.
131. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/ permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006; 107: 2200-7.
132. Hildebrandt GC, Granell M, Urbano-Ispizua A et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 67-74.
133. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007; 176: 713-23.
134. Burman AC, Banovic T, Kuns RD et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007; 110: 1064-72.
135. Trisolini R, Bandini G, Stanzani M et al. Morphologic changes leading to bronchiolitis obliterans in a patient with delayed non-infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1167-70.
136. Pardo A, Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 2002; 34: 1534-8.
137. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
138. Sime PJ, Marr RA, Gauldie D et al. Transfer of tumor necrosis factor-a to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-b1 and myofibroblasts. Am J Pathol 1998; 153: 825-32.
139. Miyazaki Y, Araki K, Vesin C et al. Expression of a tumor necrosis factor-a transgene in murine lung causes lymphocytic and fibrosing alveolitis. J Clin Invest 1995; 96: 250-9.
140. Ortiz LA, Lasky J, Lungarella G et al. Upregulation of the p75 but not the p55 TNFa receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999; 20: 825-33.
141. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-18.
142. Moore BB, Paine R 3rd, Christensen PJ et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001; 167: 4368-77.
143. Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 1992; 89: 5371-5.
144. Rabitsch W, Deviatko E, Keil F et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71: 1341-3.
145. Whitford H, Walters EH, Levvey B et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002; 73: 1793-9.
146. Iacono AT, Johnson BA, Grgurich WF et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354: 141-50.
147. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-7.
148. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-5.
149. Khalid M, Al Saghir A, Saleemi S et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25: 490-3.
150. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665-7.
151. Yanik G, Uberti J, Ferrara JLM et al. Etanercept for sub-acute lung injury following allogeneic stem cell transplantation. Blood 2003; 102: 471a.